The Limited Times

Now you can see non-English news...

Curevac: Biotech company enters the race for vaccine with a “great advantage” - competition has a problem

2020-11-18T21:19:10.129Z


When developing a corona vaccine, cooling requirements have been one of the greatest challenges so far. The Tübingen biotech company CureVac has now given the all-clear.


When developing a corona vaccine, cooling requirements have been one of the greatest challenges so far.

The Tübingen biotech company CureVac has now given the all-clear.

  • Researchers

    around the

    world are looking for a

    corona

    vaccine.

  • But the

    cooling requirements of

    a potential vaccine were considered a high hurdle.

  • Now the biotech company

    CureVac

    could have

    achieved an important achievement.

Munich - In the race to develop a

corona vaccine

, the Tübingen biotech company

CureVac could

enter the race with a big plus.

The company's own

Covid-19

* vaccine candidate will remain stable for at least three months even at plus five degrees Celsius, said

CureVac

on Thursday afternoon after evaluating internal test results.

This would allow the vaccine to be transported and stored at refrigerator temperature.

"We see a great advantage in the comparatively low cooling requirements," said a company spokesman on Thursday to Merkur.de *

Our #mRNA # COVID19 #vaccine candidate shows encouraging stability data: #CVnCoV remained stable & within defined specifications for at least three months at standard refrigerator temperature & up to 24 hours as ready- to-use vaccine at room temperature👇https: // t.co/XUcRPv0ZFC pic.twitter.com/ROqpd8KGeH

- CureVac (@CureVacRNA) November 12, 2020

For other

vaccine candidates

, the refrigeration requirements are much higher.

The active ingredient in

Moderna,

for

example, has to be

stored at minus 20 degrees.

According to reports, the

vaccine candidate from Mainz-based biotech company

Biontech even

needs arctic temperatures of minus 70 degrees for transport and logistics to ensure its effectiveness.

Corona: Transport of the vaccine is considered a "logistical nightmare"

The extremely low temperatures are considered to be one of the greatest logistical challenges when using the

vaccines

.

“This is a logistical nightmare,” they say from the industry.

At the logistics giant

Deutsche Post DHL

, for

example

, they have extensive experience in shipping vaccines or medicines that require constant cooling in the range of minus 70 degrees.

However, when

corona vaccines are delivered,

"completely different delivery sizes than before," said a company spokeswoman on Thursday.

Therefore, one is checking at the corresponding locations which adjustments are necessary in order to be able to meet the foreseeable delivery requirements.

Corona: Strong demand for ultra-freezers

Preparations for the new

corona vaccines are

also in full swing in hospitals and doctors' offices

.

According to reports, the prospect of a vaccine has

already fueled

demand for the Arctic refrigerators in the

US

.

However, the high prices represent a major hurdle for many US hospitals. Ultra-freezers cost between $ 10,000 and $ 15,000 each, depending on the equipment.

"Most hospitals in rural regions cannot afford the high-tech refrigerators," reported the US industry portal Statnews.

Here,

CureVac

could

possibly have a competitive advantage with its active ingredient and the possibility of storage at refrigerator temperatures.

According to the current planning, the Tübingen-based company intends to check its active ingredient in a large-scale phase IIb / III * test in the current fourth quarter.

The vaccine will be tested on around 30,000 subjects in Europe and Latin America.

In the first quarter of 2021, the company will then submit an application for rolling approval to the European approval authority

EMA

.

The market launch should take place in mid-2021.

The first interim results are "very promising",

CureVac declared

after evaluating the data from a total of 250 test subjects at the beginning of November.

The active ingredients of

CureVac

and

Biontech

are based on the mRNA method.

Components of the coronavirus genetic material are injected into the body in a fat solution.

In the cells, they should then stimulate the body's own immune system.

* Merkur.de is part of the nationwide Ippen Digtal editorial network.

Source: merkur

All news articles on 2020-11-18

You may like

News/Politics 2024-03-16T18:46:42.470Z
News/Politics 2024-03-18T14:18:09.201Z

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.